Sanjivani Paranteral Q4 FY26 Earnings Call Transcript

Sanjivani Paranteral reported Q4 FY26 results impacted by Middle East export disruptions from Iran-US geopolitical conflicts in March.
The company's new Pune IV fluids facility contributed INR 2.7 crore in Q4 revenue and is targeting INR 60-65 crore for FY27.
Management expects export operations to normalize in Q1 FY27 with recovery across all three business verticals - base business, IVF, and nutraceuticals.
Standalone Q4 revenue was INR 105.1 million with 14.7% EBITDA margin, while consolidated revenue stood at INR 132.1 million with 15.74% EBITDA margin.